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Pim kinases are upregulated in several forms of cancer, contributing tocell survival and tumor development, but their role in platelet functionand thrombotic disease has not been explored. We report for the first
time that Pim-1 kinase is expressed in human and mouse platelets. Genetic
deletion or pharmacological inhibition of Pim kinase results in reduced
thrombus formation but is not associated with impaired hemostasis.
Attenuation of thrombus formation was found to be due to inhibition of
the thromboxane A2 receptor as effects on platelet function were non-addi-
tive to inhibition caused by the cyclo-oxygenase inhibitor indomethacin or
the thromboxane A2 receptor antagonist GR32191. Treatment with Pim
kinase inhibitors caused reduced surface expression of the thromboxane A2
receptor and resulted in reduced responses to thromboxane A2 receptor
agonists, indicating a role for Pim kinase in the regulation of thromboxane
A2 receptor function. Our research identifies a novel, Pim kinase-dependent
regulatory mechanism for the thromboxane A2 receptor and represents a
new targeting strategy that is independent of cyclo-oxygenase-1 inhibition
or direct antagonism of the thromboxane A2 receptor that, while attenuat-
ing thrombosis, does not increase bleeding.
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ABSTRACT
Introduction
The family of Pim (proviral insertion in murine lymphoma) kinases, Pim-1, -2, 
and -3, are highly homologous serine/threonine kinases that are widely expressed
across several cell types, and are highly expressed in hematopoietic cells. Pim
kinases are constitutively active and are linked with cancer progression,1,2 with
overexpression and upregulation of Pim kinase activity associated with both
hematologic cancers and solid tumors. They function by phosphorylating their tar-
get proteins on serine/threonine residues located within the common consensus
sequence ARKRRHPS*GPPTA.1 A number of proteins that have important roles in
the regulation of cellular proliferation and survival have been identified as phos-
phorylation targets of the Pim kinases.3-6 Expressed as a short (32 kDa) or long (44
kDa) variant, the longer variant of Pim-1 kinase, Pim-1L, kinase has also been
found to regulate adenosine triphosphate-binding cassette drug transporters.7-9
Pim-1 phosphorylates both BCRP/ABCG2 and Pgp transporters enabling, through
different mechanisms, the formation of drug efflux pumps.7,9  
Pim kinases are highly expressed in hematopoietic cells where they are impor-
tant for differentiation and development of blood cells and blood cell precursors
including megakaryocytes10 and platelets.11 Whether Pim kinases are involved in
the regulation of platelet function has not been explored. Analysis of the mouse 
megakaryocyte transcriptome database12 identified multi-
ple tags for both Pim-1 and Pim-2 kinases and the mRNA
transcripts for all three Pim kinases have been identified
in the human platelet transcriptome.13,14 Interestingly
although triple knockout mice deficient in all three Pim
kinase isoforms are viable, they have been shown to have
altered hematopoiesis, but there is some dispute as to
whether disruption of all three isoforms results in alter-
ation of platelet count;10,11 however, platelet counts appear
to be unaffected by alteration of Pim-1 expression levels
in mice.15,16
Platelets rely on G protein-coupled receptors (GPCR)
such as the thromboxane A2 receptor (TPaR), ADP recep-
tors (P2Y1 and P2Y12) and the thrombin receptors (PAR1
and PAR4) to mediate platelet activation in response to
vessel damage. All platelet GPCR are regulated in some
way by receptor cycling/internalization from the platelet
surface as well as desensitization.17 Pim-1 kinase has also
been shown to have a role in the regulation of GPCR
function, through modulation of surface levels of the
CXCR4 receptor.18,19 Inhibition of Pim kinase prevents
Pim kinase-dependent phosphorylation of CXCR4 at
Ser339 and modification of the CXCR4 intracellular C ter-
minal domain, resulting in reduced surface expression
and signaling. In this study we report the presence of
Pim-1 in human and mouse platelets, and reduced throm-
bosis in Pim-1 null mice, and following pharmacological
inhibition of Pim kinase, but with no associated effect on
hemostasis. We describe a novel mechanism of action by
which Pim kinase inhibitors negatively regulate TPaR sig-
naling. 
Methods
Procedures and experiments using human blood were
approved by the University of Reading Research Ethics
Committee and protocols involving mice were performed
according to the National Institutes of Health and Medical
College of Wisconsin Institutional Animal Care and Use
Committee guidelines and as following procedures approved by
the University of Reading Research Ethics Committee.
Platelet isolation, thrombus formation assays, tail bleeding
experiments, platelet function tests, aggregometry, granule
secretion, flow cytometry, calcium imaging, immunoblotting,
image analysis, statistical analyses and materials used are
described in the Online Supplementary Methods.
Results
Expression of Pim kinase in human and mouse
platelets
Pim kinases are highly expressed in hematopoietic
cells.10,11 mRNA transcripts for all three Pim kinases have
been identified in the human and mouse platelet tran-
scriptomes13,14 and HaemAtlas mRNA expression profiles
in hematopoietic cells20 show high expression of Pim-1 in
megakaryocytes and moderate expression in platelets
(Figure 1, Online Supplementary Figure S1).21 Western blot
analysis of platelet lysates identified a protein band of 44
kDa apparent molecular mass in both human and mouse
platelet lysates indicating the expression of the larger
Pim-1 variant (Pim-1L). A protein band at 32 kDa in
mouse platelets also suggested expression of the smaller
Pim-1S. K562 and Jurkat cell lines were included as posi-
tive controls8,18,22 (Figure 1B). 
Reduced thrombus formation in Pim-1-deficient mice
To determine whether Pim-1 plays a role in the regula-
tion of platelet function and thrombosis, we measured
the ability of Pim-1-deficient mouse platelets, taken from
constitutive Pim-1-deficient mice, to form thrombi on
collagen under arterial flow in vitro. Constitutive Pim1–/–
mice were as described previously15,16 and global deletion
of Pim-1 was confirmed by polymerase chain reaction
analysis of genomic DNA (Online Supplementary Figure
S2A). Whole blood from Pim-1-/- or Pim-1+/- mice was per-
fused over collagen-coated (100 mg/mL) Vena8 biochips
for 4 min at an arterial shear rate of 1000 s-1. Thrombus
formation was significantly attenuated in blood from
Pim-1-/- mice compared to controls, indicating that Pim-1
plays a positive role in the regulation of platelet function
and thrombus formation on collagen (Figure 2A).
Constitutive Pim-1-/- mice show unaltered platelet counts
and no difference in expression levels of major platelet
adhesion receptors GPIba, GPIbβ, GPIX, GPV, GPVI and
integrins β1 and β3 was observed in Pim-1-/- platelets com-
pared to the levels in controls (Online Supplementary Figure
S2B). Interestingly, despite the reduced ability to form
thrombi, Pim-1-deficient mice showed no alteration in
hemostasis as tail bleeding was unaffected compared to
that of littermate controls (Figure 2B).  
Pim kinase inhibitors reduce thrombus formation but
do not disrupt hemostasis
As genetic deletion of Pim-1 in mice resulted in reduced
in vitro thrombus formation, we assessed the effects of the
Pim kinase inhibitor AZD1208 (100 mM) on thrombus
formation in human whole blood. The effect of the Pim
kinase inhibitor AZD1208 (100 mM) on thrombus forma-
tion on collagen in human whole blood in vitro was also
assessed. Human whole blood was pre-incubated with
vehicle control or AZD1208 and perfused over collagen-
coated (100 mg/mL) Vena8 biochips at either an arterial
shear rate (20 dynes/cm3 for 10 min) or a pathological
shear rate (135 dynes/cm3 for 5 min). Similarly to what
had been observed in Pim-1-deficient mice, a reduction in
thrombus formation and stability on collagen under flow
in vitro was also observed following AZD1208 treatment
in comparison to that seen in vehicle-treated controls
under arterial shear conditions (Figure 2C). While throm-
bus size and stability appeared reduced at arterial flow
rates, the early stages of thrombus formation, including
initial adhesion, appeared unaffected by AZD1208 treat-
ment. This was further supported by the lack of inhibi-
tion of platelet adhesion and spreading on collagen
caused by AZD1208 under static conditions (Online
Supplementary Figure S3), indicating that the initial adhe-
sion to collagen is not affected by Pim kinase inhibition.
Interestingly, enhanced inhibition of thrombus formation
on collagen was observed following treatment with
AZD1208 at pathological shear rates (~80% inhibition)
(Figure 2D) in comparison to the inhibition observed at an
arterial shear rate (~50% inhibition). In contrast to arterial
and pathological shear rates, a slight (but not significant)
reduction in thrombus formation was observed in
AZD1208-treated platelets compared to vehicle-treated
controls under venous shear conditions (Figure 2E).
Inhibitor-treated platelets appeared to form ‘woolly’ or
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‘loose’ aggregates compared to the aggregates formed in
vehicle-treated controls, but no difference in fluorescence
intensity of platelets adhered was observed. These find-
ings indicate that Pim kinase inhibition does not signifi-
cantly alter platelet adhesion and thrombus formation at
low shear rates compared to the effects observed at high-
er shear rates. To examine whether Pim kinase inhibition
could regulate thrombosis in vivo, we performed intravital
microscopy following ferric-chloride-induced injury in
mice pretreated with AZD1208 (100 µM) or vehicle con-
trol (Figure 2F). As with in vitro thrombus formation, treat-
ment with AZD1208 resulted in a dramatic attenuation in
the ability of platelets to form thrombi in vivo, at the site
of ferric-chloride-induced injury with significantly pro-
longed occlusion times observed in AZD1208-treated
mice (1463±37 s) compared to those in vehicle-treated
controls (697±72 s). This supports a role for Pim kinase in
the positive regulation of platelet function, and the anti-
platelet properties of Pim kinase inhibitors. Interestingly,
despite the dramatic attenuation in the ability of platelets
to form thrombi in vivo, as with genetic deletion, pharma-
cological inhibition of Pim kinase was not associated with
altered hemostasis. Tail bleeding assays performed in
mice indicated that treatment with AZD1208 (100 mM)
did not cause any significant increase in bleeding (Figure
2G), suggesting that despite the observed inhibitory
effect on thrombus formation, normal hemostasis is not
compromised following inhibition or genetic deletion of
Pim kinase. 
Pim kinase inhibitors reduce platelet aggregation  
To determine how Pim kinase plays a role in the regu-
lation of platelet function, human washed platelets were
pretreated for 10 min with a range of concentrations of
the pan-Pim kinase inhibitor AZD1208 before stimula-
tion with platelet agonists. As shown in Figure 3A-E pre-
treatment of platelets with AZD1208 inhibited aggrega-
tion stimulated by collagen (1 mg/mL) or the thrombox-
ane A2 (TxA2) mimetic U46619 (0.3 mM). A slight inhibi-
tion was also observed in CRP-XL stimulated platelets
(0.3 mg/mL). In contrast no inhibition of thrombin- (0.03
U/mL) or ADP- (10 mM) induced platelet aggregation was
observed following treatment with increasing concentra-
tions of AZD1208 (up to 10 mM). Treatment with four
other structurally unrelated Pim kinase inhibitors, PIM-
447 (LGH-447), SGI-1776, SMI-4a and CX6258, inhibited
platelet aggregation stimulated by either collagen or
U46619 but not thrombin, recapitulating findings with
AZD1208 and supporting a Pim kinase-dependent mode
of action (Online Supplementary Figure S4). 
Pim kinases have been shown previously to play impor-
tant roles in cell survival as Pim-2 is known to phospho-
rylate and inactivate Bcl-2-associated death promoter
(BAD).23 Inhibition of Pim kinase enables activation of
BAD and initiation of apoptosis.5 If Pim kinase inhibitors
activate apoptosis in platelets, this could cause the
observed reduction in aggregation. To investigate
whether Pim kinase inhibition triggers apoptosis in
platelets, phosphatidylserine exposure (a marker of mem-
brane flippage) was determined by measuring annexin V
binding by flow cytometry following treatment for 2 h
with AZD1208 or the BCL-2 inhibitor ABT-263, an acti-
vator of apoptosis in platelets (Online Supplementary Figure
S5A). ABT-263 treatment caused an increase in annexin V
binding but no difference was observed in AZD1208-
treated platelets compared to vehicle-treated controls
over the same incubation time. Furthermore, caspase
cleavage did not occur in platelets following 2 h of treat-
ment with Pim kinase inhibitors: AZD1208 (10 mM), SGI-
1776 (10 mM), SMI-4a (30 mM) or CX6258 (10 mM), but
did occur following treatment with the BCL-2 inhibitor
ABT-263 (Online Supplementary Figure S5B). Together
these observations suggest that Pim kinase inhibition
does not initiate platelet apoptosis. 
Pim kinase inhibitors reduce thromboxane 
A2-mediated a-granule secretion and integrin 
activation
Alpha granule secretion and activation of integrin aIIbβ3
are critical events in platelet activation and aggregation.
We investigated the effects of AZD1208 (10 µM) on a-
granule secretion and aIIbβ3 activation by measuring sur-
face P-selectin exposure and fibrinogen binding, respec-
tively. AZD1208 (10 mM) inhibited a-granule secretion
and integrin activation evoked by collagen, CRP-XL and
U46619 compared to the effects in vehicle-treated con-
A.J. Unsworth et al.
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Figure 1. Expression of Pim kinase in human and mouse platelets. (A) HaemAtlas analysis of Pim kinase mRNA expression levels. Pim kinase mRNA levels were
quantified in human megakaryocytes and a range of blood cells by analysis of gene array data. Megakaryocytes (MK), human erythroblasts (EB), human umbilical
vein endothelial cells (HUVEC), monocytes (CD14), granulocytes (CD66), mature B cells (CD19), natural killer cells (CD56), cytotoxic T cells (CD*) and helper T cells
(CD4); 10+ (lighter colors) was deemed high expression. (B) Human and mouse washed platelets (three preparations) were lysed in SDS PAGE Laemmli sample
buffer, separated on SDS PAGE gels and transferred to PVDF membranes before immunoblotting (IB) with anti-Pim-1 antibody. K562 and Jurkat cell lysates were
included as positive controls. Actin was included as a loading control. Representative blots are shown.  
  A                                                                  B
trols (Online Supplementary Figure S6). This suggests that
Pim kinase inhibitors inhibit aggregation by reducing
both integrin activation and secretion of granule contents. 
Pim kinase inhibitors reduce platelet activation to
GPVI via reduced TPaR signaling
TxA2 is synthesized and released following platelet
activation by several platelet agonists. It acts as a second-
ary mediator, boosting platelet responses to other ago-
nists, and is essential for the amplification of platelet acti-
vation and thrombus formation. Further investigation of
the inhibitory actions of AZD1208 identified significant
inhibition of U46619-evoked aggregation with half maxi-
mal inhibitory concentration (IC50) values <10 mM, con-
centrations similar to those achieved in plasma in patients
taking AZD1208,24 following stimulation by low concen-
trations of U46619 (0.03-1 mM) (Figure 4A). In contrast
the inhibitory activity of AZD1208 could be overcome at
higher concentrations of U46619 (3 and 10 mM).
Collagen-induced platelet activation is known to be
dependent on the release of secondary mediators. To test
whether the inhibition of collagen-induced platelet aggre-
gation by AZD1208 was a result of reduced activation of
the TPaR, platelet aggregation in response to a range of
collagen concentrations was measured following treat-
ment with AZD1208 (10 mM). We performed the experi-
ments in the presence or absence of indomethacin (10
mM), a cyclo-oxygenase (COX) inhibitor that prevents
TxA2 synthesis, or a TPaR antagonist GR32191 (100 nM)
to investigate whether inhibition was additive. As shown
in Figure 4B, both indomethacin and GR32191 caused an
inhibition of collagen-induced platelet aggregation, but
this was not additive to the inhibition caused by
AZD1208, suggesting that AZD1208 shares a common
Pim kinase regulates TP receptor signaling
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Figure 2. Genetic deletion and pharmacological inhibition of Pim-1 kinase attenuates thrombus formation on collagen, but does not cause bleeding. (A) DiOC6
loaded mouse whole blood from Pim1+/- (black) or Pim1-/- (red) mice was perfused through collagen-coated (100 mg/mL) Vena8Biochips at a shear rate of 1500 s-1.
(i) Representative images taken at the end of recording are shown. (ii) Thrombus formation was determined after 4 min by comparing the percentage area covered.
(B) Tail bleeding in Pim1+/- or Pim1-/- mice represented as time to cessation of bleeding (s). (C-E) DiOC6 loaded human whole blood was pretreated with vehicle (black)
or 100 mM AZD1208 (red) for 10 min before perfusion through collagen-coated (100 mg/mL) Vena8Biochips at (C) an arterial shear rate of 20 dyn/cm2, (D) a patho-
logical shear rate of 135 dyn/cm2, or (E) a venous shear rate of 4.5 dyn/cm2. The concentration of 100 mM AZD1208 was chosen because of the reduced bioavail-
ability of AZD1208 in plasma. Thrombus formation was determined after 5 min (pathological shear) or 10 min (arterial and venous shear) by comparing percentage
of maximum vehicle-treated fluorescence intensity, which measures both surface area coverage and thrombus size, in the vehicle and treated samples. (i)
Representative images taken at the end of recording are shown. (ii) Data expressed as percentage of maximum vehicle-treated fluorescence intensity. (F) Thrombus
formation was determined in vivo following ferric chloride-induced injury in mice pretreated for 10 mins with vehicle or 100 µM AZD1208. DiOC6 was used to enable
visualization of platelets. (i) representative images taken at 0, 300, 600 and 900 s. (ii) Data expressed as time to occlusion (s). (G) Tail bleeding determined as time
to cessation of bleeding (s) in mice pretreated with vehicle or 100 mM AZD1208 for 10 min. Results are mean ± standard error of mean for n≥3, *P≤0.05, **P≤0.01
****P≤0.001 in comparison to vehicle control; where normalized data are shown statistics were performed prior to normalization.
 A (i)                                         (ii)                                          B
 C (i)                                         (ii)                                        F (i)
 D (i)                                         (ii)
  E (i)                                              (ii)                                 F (ii)                                           G
TPaR.-dependent mechanism. The inhibition observed in
collagen-stimulated platelets is likely due to the loss of
TxA2 signaling, indicating that Pim kinase has a positive
regulatory role in the regulation of TPaR signaling.
Similar results were also observed following treatment
with structurally unrelated Pim kinase inhibitors SGI-
1776, PIM-447 (LGH447), SMI-4a and CX6258 in the
presence or absence of indomethacin (Online
Supplementary Figure S4D-G). In further support of this,
we also observed that AZD1208-mediated inhibition of
thrombus formation on collagen under flow occurred via
a TPaR-dependent mechanism, as indomethacin (10 mM)
did not cause further inhibition of thrombus formation
when combined with AZD1208 treatment (Figure 4C). In
support of the effects of AZD1208 being mediated via
Pim kinase, and a role for Pim kinase in the regulation of
platelet TPaR signaling, platelets from Pim1-/- mice (red)
displayed reduced fibrinogen binding, compared to con-
trols (black), following stimulation with U46619 (10 mM)
or CRP-XL (10 mg/mL) but not following stimulation with
thrombin (0.01 U/mL) (Figure 4D).
Pim kinase inhibitors inhibit platelet function 
independently of COX1
The synthesis of TxA2 in platelets is dependent on acti-
vation of COX1 following platelet stimulation. To deter-
mine whether the inhibitory effects of Pim kinase
inhibitors were due to altered COX activity, thrombox-
ane B2 (TxB2) levels (a marker of TxA2 release) were
determined following stimulation of platelets with
arachidonic  acid (a direct substrate for COX1 and the
TxA2 synthesis pathway) or collagen and compared to
the levels following treatment with indomethacin, a
COX1 inhibitor, in the presence of the TPaR antagonist
GR32191 to remove secondary TPaR feedback mecha-
nisms. While indomethacin caused almost complete
ablation of both collagen- and arachidonic acid-induced
platelet TxB2 generation, AZD1208 did not cause any
significant alterations in TxB2 generation indicating that
it does not regulate COX1 activity (Figure 5A). In further
support of AZD1208 mediating its inhibitory actions via
inhibition of TPaR receptor signaling and not inhibition
of cyclo-oxygenase activity, while AZD1208 causes
inhibition of U46619-mediated platelet aggregation,
concentrations of indomethacin that cause ablation of
platelet responses to arachidonic acid are unable to
inhibit platelet activation by the TPaR agonist U46619
(Figure 5A). 
Pim kinase inhibitors reduce signaling events 
downstream of TPaR 
The TPaR receptor is coupled to both Gq and Ga13 pro-
teins. Gq couples the TPaR to phospholipase C  which in
turn regulates calcium mobilization and the activation of
protein kinase C (PKC), key mediators of granule secre-
tion and activation of integrin aIIbβ3. Ga13 regulates the
Rho/Rho-kinase signaling pathway which regulates the
phosphorylation of myosin IIa and is important for the
regulation of cytoskeletal rearrangements and platelet
shape change.
A.J. Unsworth et al.
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(ii)                                 (ii)                                  (ii)                                  (ii)                            (ii)
  (iii)                                 (iii)                               (iii)                                (iii)                           (iii)
Figure 3. AZD1208 inhibits platelet aggregation. (A-E, i and ii) Washed human platelets were pretreated with increasing concentrations of AZD1208 (0.1, 1, 10 µM)
prior to stimulation with (A) collagen (1 mg/mL), (B) CRP-XL (0.3 mg/mL), (C) U46619 (0.3 mM), (D) thrombin (0.03 U/mL) or (E) ADP (10 mM) and aggregation moni-
tored using optical light transmission aggregometry. (i) Representative traces and (ii) quantified data are shown. (A-E, iii) Human washed platelets were pretreated
with 10 mM AZD1208 (red) or vehicle (black) prior to stimulation with (A) collagen (0.01-10 mg/mL), (B) CRP-XL (1-3 µg/mL), (C) U46619 (3 nM - 3 mM), (D) thrombin
(0.01-1 U/mL) or (E) ADP (0.1-100 µM) and aggregation was monitored after 5 min using an optical light transmission plate-based aggregometry assay; quantified
data are shown. Results are mean ± standard error mean for n≥3, *P≤0.05 ***P≤0.005 in comparison to vehicle control; where normalized data are shown statis-
tics were performed prior to normalization.
To determine whether Pim kinase regulates processes
downstream of TPaR coupled G proteins, levels of intra-
cellular calcium, PKC activity and myosin light chain
(MLC) phosphorylation were monitored following stim-
ulation with U46619. As shown in figure 5B, treatment of
platelets with AZD1208 caused a significant reduction in
calcium mobilization following stimulation with U46619
(0.3 mM) compared to vehicle-treated control platelets. In
contrast no significant difference in calcium mobilization
was observed following stimulation with ADP (10 mM)
supporting a specific role for Pim kinase in the regulation
of TPaR signaling. AZD1208 also caused a reduction both
in PKC activity and MLC (S19) phosphorylation com-
pared to vehicle controls following stimulation with
U46619 (1 mM) (Figure 5C and D). Ga13 is also associated
with the regulation of integrin aIIbβ3 outside in signaling.
25
Phosphorylation of Y773 on the integrin β3 tail which is
essential for propagation of outside-in signaling was
reduced in U46619 stimulated platelets pretreated with
AZD1208 compared to vehicle-treated control platelets
(Figure 5E). Taken together these results support a role for
Pim kinase in the positive regulation of Gq and Ga13 sig-
naling downstream of TPaR activation.
AZD1208 is not a competitive antagonist of the TPaR
As components of both Gq and G13 signaling, pathways
immediately downstream of TPaR activation, were
found to be inhibited following treatment with AZD1208
we hypothesized that the inhibitor was having direct
effect on the function of the TPaR itself. One potential
mechanism of action could be that Pim kinase inhibitors
such as AZD1208 act as antagonists of the TPaR and
inhibit the TPaR directly, independently of Pim kinase.
To determine whether AZD1208 acts as a competitive
TPaR antagonist, platelet aggregation was measured fol-
lowing treatment with increasing concentrations of
AZD1208 and stimulation with a range of U46619 con-
centrations so that the concentration relationship
between inhibitor and antagonist could be quantified by
Schild analysis. As shown in Figure 6A the inhibitory
effect of AZD1208 became saturated by 10 mM, with
higher concentrations (30, 50, 100 mM) unable to achieve
greater levels of inhibition. In contrast, increasing concen-
trations of the competitive TPaR antagonist GR32191
(Figure 5) caused non-saturable inhibition of aggregation
stimulated by U46619 and generated a linear Schild plot
with a pA2 of 8.9 which was consistent with the reported
properties of this competitive antagonist acting at the
TPaR.26 In contrast, the Schild plot for AZD1208 was lin-
ear up to a concentration of 10 mM at which point the
inhibitory effects were saturated and increasing concen-
trations of AZD1208 no longer altered the apparent EC50
of U46619. These results indicate that the concentration-
response relationship of GR32191 and U46619 in the
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Figure 4. Inhibition of thromboxane A2 signaling underlies inhibition of collagen-induced aggregation and thrombus formation by Pim kinase inhibitors. (A, B)
Human washed platelets were treated with (A) increasing concentrations of AZD1208 (1-100 mM) or vehicle control prior to stimulation with increasing concentra-
tions of U46619 (0.03-10 mM) or (B) 10 mM AZD1208 in the presence or absence of (i) indomethacin (10 µM) or (ii) the thromboxane A2 receptor antagonist GR32191
(100 nM). Platelet aggregation was monitored after 5 min of stimulation by collagen (0.01-10 mg/mL) using a 96-well plate based aggregometry assay. (C) DiOC6
loaded human whole blood was pretreated with vehicle (black) or 100 mM AZD1208 (red), in the presence of 10 mM indomethacin for 10 min before perfusion
through collagen coated (100 mg/mL) Vena8Biochips at a shear rate of 20 dyn/cm2. Thrombus formation was determined over 10 min by comparing fluorescence
intensity in the vehicle and treated samples. (i) Representative images taken at 10 min. (ii) Data expressed as the percentage of maximum fluorescence of vehicle
treated cases and normalized to an untreated (no indomethacin treatment) control, where the maximum fluorescence observed in untreated platelets is considered
to be 100% thrombus formation. (D) Fibrinogen binding in washed platelets from control (Pim1+/-)  or Pim1-/- mice was determined following stimulation with thrombin
(0.01 U/mL), U46619 (10 mM) or CRP (10 mg/mL) and expressed as percentage of positive cells. Results are mean + standard error of mean for n≥3, *P≤0.05
***P≤0.005 in comparison to vehicle control; where normalized data are shown, statistics were performed prior to normalization.
   A                                                             B (i)                                                       (ii)
 C (i)                                                          C (ii)                                                       D
aggregation assay was consistent with that of a TP recep-
tor agonist and antagonist competing to bind to the
orthosteric site, while the results with AZD1208 do not
conform to this model.
AZD1208 alters TPaR receptor surface expression 
It has been described previously that Pim kinase modu-
lates levels of the CXCR4 receptor at the surface of chron-
ic lymphocytic leukemia cells.18,19 We hypothesized that
Pim kinase inhibitors could modulate TPaR function via
a similar mechanism in platelets and measured expression
levels of TPaR following treatment with AZD1208 using
flow cytometry to investigate this further. A TPaR anti-
body that recognizes the N-terminal (extracellular) region
of the TPaR was used to determine surface expression
levels of TPaR on platelets (Figure 6C). As previously
described,27 stimulation of platelets with U46619 was
associated with a reduction in cell surface levels of TPaR,
compared to the levels on unstimulated platelets, due to
receptor internalization. Resting platelets treated with
AZD1208 (10 mM) showed reduced surface levels of the
TPaR receptor compared to the levels in vehicle-treated
controls with total levels of TPaR unaffected by
AZD1208 treatment. U46619- (1 mM) stimulated platelets
pretreated with AZD1208 also showed reduced surface
expression levels of TPaR compared to both those of
vehicle-treated controls and of platelets treated with
U46619 only. These findings indicate that reduced
U46619 signaling following treatment with AZD1208 is
linked to reduced surface expression levels of TPaR. 
AZD1208 inhibits CXCR4 signaling in human platelets
CXCR4 is expressed in platelets and is able to signal fol-
lowing stimulation with its ligand SDF-1a.28-30 To deter-
mine whether inhibition of Pim kinase alters CXCR4 sig-
naling in human platelets, aggregometry following stimu-
lation with SDF-1a (200 ng/mL) was performed in vehi-
cle- and AZD1208-treated human platelet-rich plasma.
SDF-1a caused a modest level of platelet aggregation
(~50%) in vehicle-treated platelets which was significant-
ly reduced in AZD1208- (100 mM) treated samples (~20%
aggregation) (Figure 6D). These observations indicate that
in addition to regulation of the TPaR, Pim kinase also reg-
ulates platelet CXCR4 receptor function. 
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Figure 5. AZD1208 inhibits thromboxane receptor signaling. (A) Resting and stimulated human washed platelets were treated with 10 mM AZD1208 for 10 min and
stimulated with (i) collagen (1 mg/mL) or arachidonic acid (1 mM) or (ii) U46619 (0-3 mM) in the presence and absence of indomethacin (10 mM). (i) TxB2 levels
(EnzoLife Sciences ELISA) or (ii) aggregation were monitored after 5 min of shaking. (B) Mobilization of intracellular calcium was determined in FURA-2 AM loaded
platelets following stimulation with U46619 (300 nM) or ADP (10 mM). (i) Representative traces and (ii) quantified data are shown, with data expressed as the change
in [Ca2+] (nM). (C-E) Human platelets were pre-incubated with vehicle or AZD1208 (10 mM) for 10 min and stimulated with U46619 (1 mM) for 30 s or 3 min before
lysis in SDS Laemmli sample buffer. (C) Protein kinase C (PKC) activity was determined by blotting these samples and using a phospho-site specific antibody (for the
PKC substrate recognition sequence) that detects PKC substrate phosphorylation. (D) Myosin light chain (MLC) phosphorylation at Ser19 was determined using a
phospho-specific antibody that recognizes the phosphorylated MLC. (E) Phosphorylation of the integrin β3 subunit at Y773 was determined using a phospho-specific
antibody. Actin was used to confirm equal loading. (i) Representative blots and (ii) quantified data are shown. Levels of total phosphorylation were quantified and
expressed as a percentage of the maximum phosphorylation observed in vehicle-treated, stimulated controls. Results are mean + standard error of mean for n≥3,
*P≤0.05 in comparison to vehicle controls. 
Discussion
Development of kinase inhibitors as potential thera-
peutics for solid tumors and hematologic malignancies
has been fueled by the recent successes of kinase
inhibitor therapy for cancers.1,2,31,32 Pim kinase is known to
enhance cancer progression and drug resistance, and loss
of all three Pim kinase isoforms does not affect embryo
viability, indicating that inhibition of Pim activity is likely
to be tolerable.10,11,33 In addition to its well-established role
in the regulation of cycle progression and prevention of
cellular apoptosis,3-6,23 Pim kinase has also been shown to
play roles in cell migration, potentially contributing to
metastasis and cell invasion18,19 and is also implicated in
drug resistance through activation of multidrug resistance
transporters.7-9 Pim kinase is therefore seen as a promising
potential drug target.
Pim kinases have been shown to be highly expressed in
hematopoietic cells with important roles in the develop-
ment and differentiation of megakaryocytes10 and
platelets.11,15 Deletion of Pim-1 alone has no effect on the
hematopoietic system,16 possibly indicating a level of
redundancy between the Pim kinase family members.
Kinases, however, often have broad expression profiles
across several different cell types, which increases the risk
of kinase inhibitors having unwanted side effects.
Platelets in particular rely heavily on kinase-driven signal-
ing cascades to enable them to function effectively in
response to vascular damage. Several kinase inhibitors
have been reported that affect the ability of platelets to
activate and are associated with an increased risk of
bleeding.34-36
Western blot analysis identified expression of both the
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Figure 6. AZD1208 reduces TPaR surface expression and signaling and does not act as a competitive antagonist of the TPaR. (A, B) Human washed platelets were
pre-treated with: (A) AZD1208 (1, 3, 10, 30, 50 and 100 mM) or (B) GR32191 (1, 2, 3, 5, 10, 30, 100 nM) prior to stimulation with U46619 (3 nM–3 mM) and aggre-
gation was monitored after 5 min using an optical light transmission plate-based aggregometry assay. Quantified data are shown. (i) Percentage aggregation. (ii) EC50
values from the aggregation dose-response curves determined following incubation with AZD1208 were used to plot a Schild regression plot to determine whether
AZD1208 acts as an antagonist for the TxA2 receptor. (C) Platelets were treated with AZD1208 (10 mM; 10 mins) or vehicle control. Surface expression of TPaR was
assessed using an antibody that recognizes the extracellular portion of the TPaR and detected by flow cytometry. Samples were diluted in HBS and not fixed to avoid
disruption of the membrane. Anti-DOK6 antibody was included as a negative control. (i) A representative histogram from the flow cytometer. (ii) Data are expressed
as median fluorescent intensity (MFI). (iii) Total cellular TPaR was detected by western blotting. (D) Human platelet-rich plasma was pretreated with AZD1208 (100
mM) or vehicle, as a control, for 10 min prior to stimulation with SDF-1a (200 ng/mL) and aggregation was monitored using optical light transmission aggregometry
for 5 min. (i) Representative trace and (ii) quantified data are shown. Results are mean + standard error of mean for n≥3, *P≤0.05, **P≤0.01,  ***P≤0.005 in com-
parison to vehicle-treated control; where normalized data are shown, statistics were performed prior to normalization.
 A (i)                                                   (ii)                                   B (i)                                               (ii)
 C (i)                                         (ii)                                                         (iii)
 D (i)                                                           (ii)
44 kDa and 32 kDa variants of Pim-1 kinase in human
and mouse platelets. While Pim-2 and Pim-3 were not
identified in our assays, expression of either paralog in
human and mouse platelets cannot be ruled out.
Comparison of thrombus formation on collagen under
flow in vitro established that platelets from Pim-1-defi-
cient mice showed significant attenuation in comparison
to that in wild-type controls, highlighting a role for Pim-
1 kinase in the regulation of platelet function and throm-
bus formation under arterial flow on collagen. Despite
the reduction in thrombotic potential, deletion of Pim-1
was not associated with altered hemostasis, indicating
that drugs targeting Pim kinase activity could offer an
antithrombotic therapeutic strategy that is not associated
with the increased bleeding risk usually observed with
other antiplatelet agents. 
In support of the antithrombotic potential of Pim
kinase inhibitors we determined that several structurally
different Pim kinase inhibitors, AZD1208, PIM-447, SGI-
1776, SMI-4a and CX6258, which are pan-Pim kinase
inhibitors that target all three Pim kinases, all caused inhi-
bition of platelet functional responses, including aggrega-
tion in response to GPVI agonists collagen and CRP-XL,
CXCR4 ligand SDF-1a (CXCL12) and TxA2 mimetic
U46619, but not to other GPCR agonists including throm-
bin, TRAP6 and ADP, with an inhibitory profile similar to
that observed by Lordkipanidzé et al. in a patient with a
mutation in the TP receptor.27,37 Furthermore inhibition of
collagen-induced platelet responses was found to be due
to an inhibition of TPaR signaling, as the level of platelet
aggregation observed in the presence of indomethacin or
the TPaR antagonist GR32191 was not further decreased
following treatment with AZD1208 (10 mM). Similarly to
the reduced thrombus formation observed in whole
blood from Pim-1-deficient mice, AZD1208 caused signif-
icant attenuation of thrombus formation on collagen
under flow in vitro at both arterial and pathological shear
rates and a dramatic inhibition of thrombus formation in
vivo (Figure 2). Interestingly, however, no effect on
platelet adhesion and thrombus formation at venous flow
rates was observed following treatment with AZD1208;
this, combined with the lack of effect on bleeding in mice
following damage to the tail vein, suggests that although
Pim kinase inhibition or deficiency reduces thrombus for-
mation under high arterial shear, this does not alter
thrombus formation or hemostasis at venous or low
shear. This absence of effect is likely due to the lack of
inhibition of PAR or P2Y receptor-mediated platelet acti-
vation by Pim kinase inhibitors. Previous studies have
shown that while GPVI deficiency or inhibition has vary-
ing effects in tail bleeding assays,38,39 PAR or P2Y12 defi-
ciency or P2Y1 inhibition results in significant increases in
tail bleeding and alteration of hemostasis in mice.39-41 As
initial adhesion to collagen is unaffected following treat-
ment with AZD1208, maintenance of PAR and P2Y
receptor responses may compensate for the lack of TP
receptor signaling, allowing for normal hemostasis. The
lack of bleeding effect following treatment with
AZD1208 is consistent with the lack of reported bleed-
ing-related adverse effects in patients in a recent phase I
clinical study investigating the efficacy of AZD1208 in
solid and hematologic cancers.24 This provides further evi-
dence that Pim kinase inhibitors may not be associated
with drug-induced platelet dysfunction-related bleeding
events and points to future use of Pim kinase inhibitors as
a possible treatment strategy for individuals with
increased risk of cardiovascular disease and atherosclero-
sis, conditions associated with pathological shear rates.
Investigation into how Pim kinases elicit their inhibito-
ry effects on TPaR signaling, revealed that AZD1208
inhibited TPaR downstream signaling events, pointing to
upstream regulation of TPaR signaling most likely via
direct regulation of the TPaR. It has previously been
described that Pim-1 kinase regulates CXCR4 activity in
Jurkat and chronic lymphocytic leukemia cells via regula-
tion of surface expression levels of the receptor.18,19
Inhibition or deletion of Pim kinase reduces surface
expression levels of CXCR4 and inhibits CXCL12/SDF-1
signaling.29,30  Similarly, in our study we identified reduced
surface expression levels of TPaR in platelets following
treatment with AZD1208 compared to the levels in vehi-
cle-treated controls. 
The TPaR signaling pathway is a key target to reduce
cardiovascular disease-related thrombotic events and
inflammation in patients. Despite widespread use, cur-
rently available GPCR-targeted therapies are associated
with variable outcomes and adverse side effects in
patients. Aspirin is the ‘gold standard’ antiplatelet agent
for the prevention of arterial thrombosis. Aspirin targets
platelet TPaR signaling via an indirect route, by inhibiting
COX1, the enzyme that controls synthesis of TxA2.
Aspirin, however, has dose-limiting off-target effects on
COX2, an enzyme involved in synthesis of endogenous
inhibitors of platelet function that can increase the risk of
thrombosis when repressed. Aspirin is also less effective
in patients suffering from diabetes, hypertension and
obesity, and is associated with an increased risk of severe
bleeding42 with one recent meta-analyses suggesting that
in low-risk individuals the harms of aspirin outweigh the
cardiovascular benefits.43-45 Our findings suggest that Pim
kinases may be a safer target to control thrombosis.
The mechanism underlying the regulation of TPaR sig-
naling by Pim-1 kinase requires further investigation. In
other cell types the 44 kDa variant of Pim-1 kinase, Pim-
1L is localized to the plasma membrane and associated
with the phosphorylation and regulation of several mem-
brane proteins, while the smaller 32 kDa variant Pim-1S
predominantly localizes to the cytosol and nucleus.7,46
One possibility is that Pim kinase phosphorylates the
TPαR. controlling its surface expression levels, similar to
the mechanism observed for CXCR4 in chronic lympho-
cytic leukemia cells. Sequence alignments of the Pim
kinase substrate recognition sequence have identified
four putative Pim kinase phosphorylation sites within the
TPaR sequence, including one within the first intracellu-
lar loop, a region that has previously been shown to be
associated with TPaR surface expression and receptor
function.27 Pim kinase inhibition may therefore disrupt
phosphorylation of the receptor and reduce surface
expression via increasing its internalization or preventing
the dynamic process of receptor recycling to the surface.
It is also possible that Pim kinase does not phosphorylate
the receptor directly and instead orchestrates interactions
with other proteins that regulate receptor surface expres-
sion.18,19 
This work identifies a novel, Pim kinase-dependent reg-
ulatory mechanism for the TPaR and represents a new
targeting strategy that is independent of COX1 inhibition
or direct antagonism of the TPaR that, while reducing
thrombosis, does not increase the risk of bleeding. 
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